1Van Brubben MC J, Wrlgrcen B, Rijke RPM, et al. Heparin and heparinoids prevent the binding of immune complexes containing nuclesomal antigens to the GBM and delay nephritis in MRL/lpr mice. Kidney Int ,1996, 50:1555-1564.
2Wang Y,Hu O,Madre JA.Amelioration of lupus-like autoimmune disease in NZB/W F 1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA, 1996, 93:8563-8568.
3Charles PJ, Smeenk RJT, Dejong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha:findings in open-label and randomiz
4Sato EI,Assis LS,Lourenzi VP,et al. Long-term thalidomide use in refraetory cutaneous lesions of systemic lupus erythermatosus. Rev Assoc Med Bras, 1998,44:289-293.
5Clynes R,Dumitru C,Ravetch JV.Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science, 1998,279:1052-1054.
6Balomenos D,Rumold R,Theofilopoulos AN.Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice.J Clin Invest, 1998,101:364-371.
7Alvarez NYJ, Cobrarrubias CA, Escalante TF, et al. Bromocriptine in systemic lupus erythematosus: a double-blind randomized, placebo-controlled study. Lupus ,1998, 7:414-419.
8Van Vollenhoven RF, Park JL, Genovese MC, et al. A double-blind,placebo-controlled, clinical trial of dehydrcepiandrosterone in severe systemic lupus erythematosus. Lupus, 1999,8:181 - 187.
9Blanco R, Martinez VM, Redriguezvalverde V, et al. Successful therapy with danazol in refractory autoimmune thrombocytopoenia associated with rheumatic diseases. Br J Rheumatol,1997, 36:1095-1099.
10Levy Y, Sherer Y, Ahmed A, et al. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response. Lupus,1999, 8:705-712.
